Literature DB >> 9630363

Responses to endothelium-dependent agonists in subcutaneous arteries excised from hypercholesterolaemic men.

T V Lewis1, B A Cooper, A M Dart, J P Chin-Dusting.   

Abstract

1. Vasomotor function of the vascular endothelium was examined in human subcutaneous arteries excised from 8 hypercholesterolaemic and 7 normolipidaemic subjects. 2. Left gluteal skin biopsies were performed under local anaesthesia. Subcutaneous arteries were isolated and two vessels from each subject mounted in separate myographs. A 20 ml fasting blood sample was taken at the time of the biopsy. 3. Hypercholesterolaemic subjects had either never been treated with lipid lowering therapy or therapy had been stopped at least two weeks before the study (n = 2). At the time of the study total plasma cholesterol levels (control: 4.6+/-0.3 vs hypercholesterolaemic: 8.3+/-0.6 mmol l(-1): P < 0.01) were significantly elevated in hypercholesterolaemic subjects when compared with controls. 4. Full concentration-response curves to the vasoconstrictor noradrenaline and the vasodilators acetylcholine and substance P were constructed. A single point concentration-response to sodium nitroprusside (10 microM) was also obtained. Dilator responses were obtained in vessels pre-constricted with a submaximal concentration of noradrenaline. Vessels were then incubated for 30 min with either L- or D-arginine (10 microM) and the concentration-response curves to the three dilator agonists repeated in the presence of the amino acid. 5. Maximum relaxation responses to acetylcholine (control vs hypercholesterolaemic: 83.3+/-6.1% vs 47.4+/-13.5%; P < 0.05), but not to substance P or sodium nitroprusside, were dampened in the hypercholesterolaemic group when compared with controls. 6. Neither incubation with L-arginine nor D-arginine had any effect on maximum relaxation responses to acetylcholine in either the control group (pre L-arginine vs plus L-arginine: 83.3+/-6.1 vs 82.3+/-5.5%, pre D-arginine vs plus D-arginine: 98.9+/-1.2 vs 98.2+/-1.1%) or the hypercholesterolaemic group (pre L-arginine vs plus L-arginine: 47.4+/-13.5 vs 55.3+/-14.3%, pre D-arginine vs plus D-arginine: 43.3+/-13.6 vs 65.4+/-12.3%). 7. When results from the two study groups were pooled, the strongest predictor of maximum relaxation obtained to acetylcholine was apolipoprotein A1 (r = 0.67; P = 0.001). 8. In conclusion, relaxation responses mediated by the endothelium-dependent agonist acetylcholine, but not by substance P, are impaired in hypercholesterolaemic patients. L-Arginine did not improve the impaired relaxation responses to acetylcholine. We suggest that impaired endothelium-dependent relaxation is specific to acetylcholine and not to an abnormal L-arginine-nitric oxide pathway in subcutaneous arteries excised from this study group.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9630363      PMCID: PMC1565360          DOI: 10.1038/sj.bjp.0701800

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  3 in total

Review 1.  Statins and blood pressure regulation.

Authors:  C Borghi; M Veronesi; M G Prandin; A Dormi; E Ambrosioni
Journal:  Curr Hypertens Rep       Date:  2001-08       Impact factor: 5.369

Review 2.  Use of lipid-lowering drugs and blood pressure control in patients with arterial hypertension.

Authors:  Claudio Borghi; Ada Dormi; Maddalena Veronesi; Vincenzo Immordino; Ettore Ambrosioni
Journal:  J Clin Hypertens (Greenwich)       Date:  2002 Jul-Aug       Impact factor: 3.738

3.  Additive beneficial effects of valsartan combined with rosuvastatin in the treatment of hypercholesterolemic hypertensive patients.

Authors:  Ji-Yong Jang; Sang-Hak Lee; Byung Soo Kim; Hong Seog Seo; Woo-Shik Kim; Youngkeun Ahn; Nae-Hee Lee; Kwang Kon Koh; Tae-Soo Kang; Sang-Ho Jo; Bum-Kee Hong; Jang-Ho Bae; Hyoung-Mo Yang; Kwang Soo Cha; Bum Soo Kim; Choong Hwan Kwak; Deok-Kyu Cho; Ung Kim; Joo-Hee Zo; Duk-Hyun Kang; Wook Bum Pyun; Kook Jin Chun; June Namgung; Tae-Joon Cha; Jae-Hyeon Juhn; YeiLi Jung; Yangsoo Jang
Journal:  Korean Circ J       Date:  2015-05-27       Impact factor: 3.243

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.